Medicofarma Biotech Spolka Akcyjna
0.35
PLN
-0.01
(-1.68%)
ISIN
PLINBOK00010
Return %
Stock
S&P 500
1Y
-42.86
14.20
3Y
-67.85
81.12
5Y
-85.02
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Robert Kilczewski Cezary
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Warsaw Poland
- IPO Date
- Nov 27, 2008
- Website
- medicofarmabiotech.pl
- Similar Companies
- Business
- Medicofarma Biotech Spolka Akcyjna, a biotechnology company, engages in the research, design, development, and commercialization of innovative medicines, therapeutic solutions, and biotechnology products in Poland and international markets. The company focuses on the development of novel therapies and contract scientific services, offering a portfolio that includes: innovative oncology therapies, featuring first-in-class RNA-based candidates encapsulated in lipid nanoparticles (LNP) for the treatment and recurrence prevention of glioblastoma multiforme (GBM), ovarian cancer, breast cancer, and hepatic cancer; therapeutic products for gastrointestinal indications, including irritable bowel syndrome (IBS) and oral cavity diseases; in vitro molecular diagnostics, including the MediPAN series of genetic diagnostic test kits developed in collaboration with scientific research institutions; contract research and development (R&D) services; formulation design and analytical laboratory testing for generic pharmaceuticals, functional foods, dietary supplements, and dermocosmetics; and regulatory compliance, quality control, and contract manufacturing support for pharmaceutical and medical device companies. The company conducts its research and experimental development operations through specialized research facilities, including Good Laboratory Practice (GLP)-certified laboratories located in Poznan and Lublin, Poland. In recent developments, Medicofarma Biotech Spolka Akcyjna, formerly known as Inbook S.A. prior to its corporate restructuring and strategic transformation into a dedicated biotechnology enterprise, has advanced its preclinical oncology programs with in vivo studies demonstrating tumor reduction in glioblastoma post-resection models; expanded its intellectual property portfolio through multiple pending domestic and Patent Cooperation Treaty (PCT) patent filings covering proprietary active substances and LNP formulation delivery technologies; deepened strategic research partnerships with academic institutions, including the Institute of Bioorganic Chemistry of the Polish Academy of Sciences; and pursued a long-term corporate strategy focused on advancing drug candidates into clinical trial phases and preparing for a potential listing transition to the main market of the Warsaw Stock Exchange. Medicofarma Biotech Spolka Akcyjna was founded in 2001, operates as a subsidiary of Vitama Spolka Akcyjna, and is headquartered in Warsaw, Poland.